Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 og 5.

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

piramal critical care b.v. - fentanylum cítrat - stungulyf, lausn - 50 míkróg/ml

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

merck sharp dohme limited - vorapaxarsúlfat - hjartadrep - blóðþurrðandi lyf - zontivityis ætlað til að draga af atherothrombotic atburðum í fullorðinn sjúklinga með - sögu um kransæðastíflu (mi)co-gefið með asetýlsalisýlsýru (asa) og, þar sem við, eftir að; eða - einkennum útlæga slagæð sjúkdómur(pad), sam-gefið með asetýlsalisýlsýru (asa) eða, þar sem við, eftir að.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - Æxlishemjandi lyf - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - aprepitantum inn - hart hylki - 125 mg/80 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 150 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 300 mg